Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage

Table 2 Incidence and duration of complications in the two groups (n, %) (mean ± SD)

Complications	Late treatment group (n = 38)		Early treatment group (n = 38)
	Cases (%)	Duration (d)	Cases (%)	Duration (d)
ARDS	18 (47.4)	12.7 ± 21.0	21 (55.3)	2.7 ± 3.3b
Renal failure	9 (23.7)	5.3 ± 7.3	7 (18.4)	1.3 ± 0.5b
Acute hepatitis	19 (50.0)	7.0 ± 7.1	17 (44.7)	3.2 ± 2.3b
Shock	6 (15.8)	4.8 ± 3.1	9 (23.7)	1.7 ± 0.4a
Encephalopathy	4 (10.5)	9.5 ± 11.0	4 (10.5)	2.3 ± 1.9b
Enteroparalysis	27 (71.1)	3.5 ± 2.2	29 (76.3)	2.2 ± 1.4b

^aP < 0.05,

^bP < 0.01 vs late treatment group; ARDS: acute respiratory distress syndrome.